Jiangsu Hengrui Pharmaceuticals stock

600276 · SSE · CNY

Compare Jiangsu Hengrui Pharmaceuticals
¥47.00Change from previous close: +0.26%Absolute change: +¥0.12

Close · November 20, 2026

Price history

−22.48% over the period

1 year: from ¥60.63 (November 20, 2025) to ¥47.00 (November 20, 2026), −22.48%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026¥47.00
October 30, 2026¥48.46
September 30, 2026¥47.20
August 31, 2026¥46.07
July 31, 2026¥54.08
June 30, 2026¥52.04
May 29, 2026¥50.19
April 30, 2026¥53.88
March 31, 2026¥55.22
February 27, 2026¥56.56
January 30, 2026¥58.16
December 31, 2025¥59.57
November 28, 2025¥62.08
November 20, 2025¥60.63

At a glance

  • The company

    Develops, manufactures and commercializes pharmaceutical medicines across oncology, cardiovascular, immunological, neuroscience, pain management and other therapeutic areas

  • Latest results

    Quarter to September 30, 2026 · EPS ¥0.37 (estimate ¥0.34)

TickerLandia's take on Jiangsu Hengrui Pharmaceuticals

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low¥41.89
52-wk high¥65.83

−28.60% from the 52-week high

Analysts · 18 analysts

Average target¥71.64+52.42% vs. price

Buy 18 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: Jiangsu Hengrui Pharmaceuticals

Compared with similar companies: very high financial strength.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Jiangsu Hengrui Pharmaceuticals is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Jiangsu Hengrui Pharmaceuticals's P/E today is 39.8, below the median of its last 10 fiscal years (62.1; between 41.3 and 93.8 from 2016 to 2025). Jiangsu Hengrui Pharmaceuticals's P/E (trailing 12 months): 35.1, −15% against the median of a group of 11 similar companies (41.2).

P/E compared with its history

Compared with 11 similar companies

Jiangsu Hengrui Pharmaceuticals's metrics compared with similar companies
MetricJiangsu Hengrui PharmaceuticalsPosition in the groupBand
P/E (trailing 12 months)35.1Middle
Forward P/E30.9Middle
Operating margin27.4%Middle
ROE13.9%Middle
Debt/equity0.00Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Jiangsu Hengrui Pharmaceuticals. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥8.95B

Latest quarter · Q3 2026

Net income

¥2.46B

Latest quarter · Q3 2026

Quarterly net margin

27.5%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
¥311.95B
P/E
35.1
EPS
¥1.34
Volume
54.69M
Daily trading
€384.65M
Dividend yield
0.43%
Last ex-dividend on May 27, 2026

How Jiangsu Hengrui Pharmaceuticals is changing

All results
  • Revenue grew 2.7% a year on average over the last 5 years

  • Operating margin rose from 14.4% to 25.6%

  • Profits turn into cash: free cash flow equal to 108% of net income

Returns

Jiangsu Hengrui Pharmaceuticals returns with dividends

¥1,000 invested in Jiangsu Hengrui Pharmaceuticals 5 years ago, on November 22, 2021, would be worth ¥922 today with dividends reinvested: −7.83% in total, −1.62% per year. On price alone it would be ¥903 (−9.65%).

PeriodJiangsu Hengrui Pharmaceuticals¥1,000 becomes
1 month−0.95%¥991
6 months−7.75%¥922
Year to date−21.10%¥789
1 year−22.17%¥778
3 years+0.21%¥1,002
5 years−7.83%¥922
10 years+185.57%¥2,856

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Jiangsu Hengrui Pharmaceuticals: technical analysis

Jiangsu Hengrui Pharmaceuticals shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 51.0% below its all-time closing high (¥95.84, December 25, 2020).

Trend
No clear trend
RSI (14 sessions)
45
Between 30 and 70
vs 200-session average
−9.21%

Support and resistance

Price areas where Jiangsu Hengrui Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance¥55.98+19.11%2 touches, last on August 10, 2026
  2. Resistance¥52.40+11.49%5 touches, last on August 7, 2026
  3. Resistance¥51.05+8.61%2 touches, last on November 6, 2026
  4. Last price¥47.00
  5. Support¥45.32−3.57%2 touches, last on October 23, 2026
  6. Support¥44.54−5.24%2 touches, last on October 14, 2026

Volatility and risk

Volatility (60 sessions, annualised)
29.5%
Largest fall in the last year
−33.87%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Jiangsu Hengrui Pharmaceuticals: seasonality

Average monthly price change over 26 years

−1.1%Jan+1.9%Feb+3.3%Mar+3.3%Apr+2.4%May+0.3%Jun+1.7%Jul−0.2%Aug+4.5%Sep+1.0%Oct+2.0%Nov+3.0%Dec

Over the last 26 years, the strongest month for Jiangsu Hengrui Pharmaceuticals has been September: +4.51% on average, positive in 20 years out of 26. The weakest has been January: −1.08% on average, positive in 11 years out of 26. November, the current month, has been positive in 15 years out of 26 (+2.01% on average).

Show chart data
MonthAverageMedianPositive years
January−1.08%−1.53%11 of 26
February+1.91%+1.56%14 of 26
March+3.32%+2.93%15 of 26
April+3.34%+1.62%17 of 26
May+2.44%+2.22%15 of 26
June+0.35%+1.90%14 of 26
July+1.73%+1.24%16 of 26
August−0.22%−0.13%13 of 26
September+4.51%+4.57%20 of 26
October+1.01%+0.99%13 of 26
November+2.01%+1.72%15 of 26
December+3.00%+1.36%14 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Jiangsu Hengrui Pharmaceuticals and its competitors

Patients and healthcare providers in China and abroad are the people Jiangsu Hengrui Pharmaceuticals serves with medicines it researches, develops, manufactures and commercializes to address clinical needs that remain unmet. Its medicines cover oncology, metabolic and cardiovascular diseases, immunological and respiratory conditions, neuroscience, pain management, infectious diseases, hematological disorders, ophthalmology and autoimmune illnesses, among other areas.

Headquarters
Lianyungang, China
Employees
20,602
Founded
1970
Chief executive
Ji Feng
Jiangsu Hengrui Pharmaceuticals and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Jiangsu Hengrui Pharmaceuticals600276$46.71B27.4%35.1−7.75%
Sun Pharmaceutical IndustriesSUNPHARMA$48.8B23.3%41.2+0.24%
Divi's LaboratoriesDIVISLAB$32.03B34.0%88.2+62.20%
Takeda Pharmaceutical4502$70.21B16.6%312.4+32.69%
Hansoh Pharmaceutical Group3692$23.77B37.3%25.0−8.51%
Torrent PharmaceuticalsTORNTPHARM$19.25B22.2%79.2+5.88%

Same industry or related industries, similar size. Compare Jiangsu Hengrui Pharmaceuticals with its competitors · Full profile